# Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

> **NCT01894165** · PHASE1 · COMPLETED · sponsor: **Origin Biosciences** · enrollment: 24 (actual)

## Conditions studied

- Molybdenum Cofactor Deficiency (MoCD)
- Rare Autosomal Recessive Disorder
- Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)

## Interventions

- **DRUG:** ALXN1101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01894165
- **Lead sponsor:** Origin Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894165, "Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01894165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*